The pharma giant Lupin Pharma Canada Pvt. Ltd. has announced the release of long-acting Propranolol capsules in the country. The counterpart of Inderal LA (long-acting), this drug effectively treats the heart condition. Inderal™ LA was discontinued for patients and practitioners, resulting in the release of this extended-release drug.
The medical needs of the patients in Canada will be addressed by the release of this drug, thus improving accessibility.
The capsules are available in four doses: 60 mg, 80 mg, 120 mg, and 160 mg. To be prescribed depending on the severity of the condition. The affordability of the drugs was a significant focus area for the company.
The accessibility of the drug was ensured to the Canadian patients post-discontinuation of the counterpart. The newly introduced drug is a singular extended-release version of Propranolol.
The drug is proven to mitigate the symptoms while improving the patient’s quality of life and compliance.
The company’s president, Dr. Sofia Mumtaz, expressed her delight over the drug’s launch. The launch underscored its aim to improve accessibility and affordability for Canadian patients.
The president for Lupin in Canada also added that the introduction ensured Canadians had access to essential medicines. “We have diligently worked to build our portfolio to include Propranolol LA ensuring patients have access to the essential medicines.” Dr. Sofia Mumtaz shared.
She added, “This launch signifies our commitment to fostering healthcare solutions that truly make a difference.”
The company warned the patients that they should consult their physicians before switching to Propranolol LA.
The third–largest pharmaceutical company in the U.S. is also a leader in the anti-diabetic, respiratory, and cardiovascular segments.
The launch resulted in a 2% rise in Lupin shares a day after the subsidiary was released. The drug is yet to be approved by the FDA, which is expected to be received soon.